This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

VIVUS Announces AANP Scientific Presentations

Presentation Title

Weight Loss and Improvements in Quality of Life Associated With Baseline Body-Mass Index in Obese and Overweight Patients Treated With Phentermine/Topiramate Extended-Release

Authors: Timothy Church, MD a; Ronette L. Kolotkin, PhD b; Santosh T. Varghese, MD c Affiliations: a Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA; bDuke University Medical Center and Obesity and Quality of Life Consulting, Durham, NC; cVIVUS, Inc., Mountain View, CA, USA

Conference

AANP 2013: American Association of Nurse Practitioners 28 th National Conference

June 19-23, 2013

The Venetian, The Palazzo, and Sands Expo and Convention Center, Las Vegas, Nevada

Date/Time

Poster Presentation Date:

  • Poster Presentation: Thursday, June 20, 4:00 PM to 6:00 PM; Friday, June 21, 4:00 PM to 6:00 PM; Saturday, June 22, 12:30 PM to 2:15 PM
  • Exhibit Hall Hours: Thursday, June 20, 10:45 AM to 1:00 PM; Friday, June 21, 11:00 AM to 6:00 PM; Saturday, June 22, 11:00 AM to 2:30 PM

Session Location: The Venetian, The Palazzo and Sands Expo and Convention Center, Exhibit Hall

Presentation Title

Prevention of Type 2 Diabetes Mellitus in Subjects With Prediabetes Using Phentermine and Topiramate Extended-Release for 1 Year

Authors: Miriam M. Rueger, RN, MPH, RD, CDE a; W. Timothy Garvey, MD a; Lan T. Nguyen b ; Craig A. Peterson, MS b

Affiliations: aUniversity of Alabama at Birmingham, Birmingham, AL; bVIVUS, Inc., Mountain View, CA

About Qsymia

Qsymia ® (phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs